Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to $45,362.

  • Addex Therapeutics' Gains from Investment Securities rose 1496.27% to $45,362 in Q2 2025 from the same period last year, while for Jun 2025 it was $153,235, marking a year-over-year decrease of 70.11%. This contributed to the annual value of -$138.98 for FY2021, which is 97.39% up from last year.
  • Latest data reveals that Addex Therapeutics reported Gains from Investment Securities of $45,362 as of Q2 2025, which was up 3.08% from $44,008 recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Gains from Investment Securities registered a high of $432,751 during Q1 2022, and its lowest value of -$3,249 during Q2 2024.
  • For the 3-year period, Addex Therapeutics' Gains from Investment Securities averaged around $122,182, with its median value being $46,412 (2024).
  • In the last 5 years, Addex Therapeutics' Gains from Investment Securities tumbled by 101.33% in 2024 and then surged by 1,496.27% in 2025.
  • Over the past 4 years, Addex Therapeutics' Gains from Investment Securities (Quarterly) stood at $371,210 in 2022, then increased by 0.32% to $372,401 in 2023, then slumped by 87.26% to $47,462 in 2024, then surged by 1,496.27% to $45,362 in 2025.
  • Its last three reported values are $45,362 in Q2 2025, $44,008 for Q1 2025, and $47,462 during Q4 2024.